MX2017012829A - Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos. - Google Patents

Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.

Info

Publication number
MX2017012829A
MX2017012829A MX2017012829A MX2017012829A MX2017012829A MX 2017012829 A MX2017012829 A MX 2017012829A MX 2017012829 A MX2017012829 A MX 2017012829A MX 2017012829 A MX2017012829 A MX 2017012829A MX 2017012829 A MX2017012829 A MX 2017012829A
Authority
MX
Mexico
Prior art keywords
humanized
mhc
human
cell
correceptor
Prior art date
Application number
MX2017012829A
Other languages
English (en)
Inventor
J Murphy Andrew
Macdonald Lynn
Gurer Cagan
Kyratsous Christos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56926255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017012829(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2017012829A publication Critical patent/MX2017012829A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente descripción se describen animales no humanos (por ejemplo, roedores, por ejemplo, ratones o ratas) genéticamente modificados para expresar un correceptor de células T humanizado (por ejemplo, CD4 y/o CD8 humanizado (por ejemplo, CD8a y/o CD8ß), un receptor de célula T (TCR) humano o humanizado que comprende un dominio variable codificado mediante al menos un segmento de gen de región variable del TCR humano y/o un complejo mayor de histocompatibilidad que se une al correceptor de célula T humanizado (por ejemplo, MHC II humano o humanizado (por ejemplo, cadenas del MHC II a y/o MHC II ß) y/o MHC I (por ejemplo, MHC Ia) respectivamente, y opcionalmente, microglobulina ß2 humana o humanizada). Se proporcionan, además, los embriones, tejidos, y células que los expresan. Se proporcionan, además, métodos para crear un animal genéticamente modificado que expresa al menos un correceptor de células T humanizado (por ejemplo, CD4 y/o CD8 humanizados), al menos un MHC humanizado que se asocia con el correceptor de células T humanizado (por ejemplo, MHC II y/o MCH I humanizados, respectivamente) y/o el TCR humanizado. Se proporcionan, además, métodos para el uso de los animales genéticamente modificados que montan una respuesta inmunitaria de células T sustancialmente humanizada para desarrollar agentes terapéuticos humanos.
MX2017012829A 2015-04-06 2016-04-06 Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos. MX2017012829A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562143687P 2015-04-06 2015-04-06
US201562158804P 2015-05-08 2015-05-08
US201562186935P 2015-06-30 2015-06-30
PCT/US2016/026260 WO2016164492A2 (en) 2015-04-06 2016-04-06 Humanized t cell mediated immune responses in non-human animals

Publications (1)

Publication Number Publication Date
MX2017012829A true MX2017012829A (es) 2018-02-23

Family

ID=56926255

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017012829A MX2017012829A (es) 2015-04-06 2016-04-06 Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.
MX2023002653A MX2023002653A (es) 2015-04-06 2017-10-05 Respuestas inmunitarias mediadas por celulas t humanizadas en animales no humanos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023002653A MX2023002653A (es) 2015-04-06 2017-10-05 Respuestas inmunitarias mediadas por celulas t humanizadas en animales no humanos.

Country Status (24)

Country Link
US (2) US11259510B2 (es)
EP (2) EP4248744A3 (es)
JP (5) JP6796597B2 (es)
KR (2) KR102699643B1 (es)
CN (2) CN107666828B (es)
AU (3) AU2016246698B2 (es)
CA (2) CA3223798A1 (es)
DK (1) DK3280257T3 (es)
ES (1) ES2954865T3 (es)
FI (1) FI3280257T3 (es)
HR (1) HRP20231039T1 (es)
HU (1) HUE064168T2 (es)
IL (4) IL297097B2 (es)
LT (1) LT3280257T (es)
MX (2) MX2017012829A (es)
NZ (1) NZ736031A (es)
PL (1) PL3280257T3 (es)
PT (1) PT3280257T (es)
RS (1) RS64540B1 (es)
RU (1) RU2732628C2 (es)
SG (2) SG10201909320UA (es)
SI (1) SI3280257T1 (es)
SM (1) SMT202300408T1 (es)
WO (1) WO2016164492A2 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
DK2770821T3 (da) 2011-10-28 2017-11-27 Regeneron Pharma Genetisk modificerede major histocompatibility-kompleks-mus
EP2770822B9 (en) 2011-10-28 2019-12-11 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
EP2771357B1 (en) 2011-10-28 2018-07-18 Regeneron Pharmaceuticals, Inc. Genetically modified t cell receptor mice
EP3543253B1 (en) 2013-02-20 2024-03-27 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
HRP20181866T1 (hr) 2013-02-22 2019-01-25 Regeneron Pharmaceuticals, Inc. Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti
EP3376857B1 (en) 2015-11-20 2021-02-24 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized lymphocyte-activation gene 3
PT3422845T (pt) 2016-02-29 2021-08-26 Regeneron Pharma Roedores com um gene tmprss humanizado
KR102784608B1 (ko) 2016-06-03 2025-03-27 리제너론 파마슈티칼스 인코포레이티드 외인성 말단 데옥시뉴클레오타이드 전달효소를 발현하는 비인간 동물
EP4276185A3 (en) 2017-09-29 2024-02-21 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized ttr locus and methods of use
WO2019076486A1 (en) * 2017-10-19 2019-04-25 Cellectis TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR ENHANCED IMMUNE CELL THERAPY
CN111655031B (zh) 2017-11-30 2022-11-18 瑞泽恩制药公司 包含人源化trkb基因座的非人动物
EP3543699B1 (en) 2018-03-24 2021-08-04 Regeneron Pharmaceuticals, Inc. Methods for identifying hla-associated tumor peptides
IL314733A (en) 2018-03-26 2024-10-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
US11589562B2 (en) 2018-07-16 2023-02-28 Regeneran Pharmaceuticals, Inc. Mouse model of DITRA disease and uses thereof
EA202191107A1 (ru) 2018-10-23 2021-09-17 Ридженерон Фармасьютикалз, Инк. T-клеточные рецепторы ny-eso-1 и способы их применения
EP3873500A4 (en) * 2018-10-31 2023-01-11 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
EP3873540A4 (en) 2018-10-31 2022-07-27 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
IL286905B2 (en) 2019-04-04 2024-06-01 Regeneron Pharma Non-human animals containing the human coagulation factor 12 locus
CA3151385A1 (en) 2019-05-01 2020-11-05 Pact Pharma, Inc. Compositions and methods for the treatment of cancer using a tet2 engineered t cell therapy
KR20220016869A (ko) 2019-06-04 2022-02-10 리제너론 파마슈티칼스 인코포레이티드 베타-슬립 돌연변이를 갖는 인간화 ttr 좌위를 포함하는 비-인간 동물 및 사용 방법
BR112021022722A2 (pt) 2019-06-07 2022-01-04 Regeneron Pharma Animal não humano, célula de animal não humana, genoma de animal não humano, gene de albumina animal não humana humanizada, vetor de alvejamento, método de avaliação da atividade de um reagente, e, método de otimização da atividade de um reagente
EP4041868A1 (en) * 2019-10-03 2022-08-17 Regeneron Pharmaceuticals, Inc. High-throughput method to screen cognate t cell and epitope reactivities in primary human cells
WO2021150804A1 (en) 2020-01-24 2021-07-29 Regeneron Pharmaceuticals, Inc. Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof
CN118511853A (zh) * 2021-03-31 2024-08-20 瑞泽恩制药公司 包含具有改善的tcrb组库多样性的人源化细胞免疫系统组分的基因修饰的小鼠
WO2023092119A2 (en) 2021-11-22 2023-05-25 Ludwig Institute For Cancer Research Ltd Methods for predicting responsiveness to a cancer therapy
CN113999873B (zh) * 2021-12-31 2022-05-20 北京市疾病预防控制中心 一种基因修饰的非人动物的构建方法及其应用
CN115074368B (zh) * 2022-06-09 2023-08-08 澳门科技大学 一种耐药型类风湿性关节炎动物模型的构建及其应用
WO2024064860A1 (en) 2022-09-22 2024-03-28 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing components of human cellular immune system
IL320128A (en) 2022-10-31 2025-06-01 Regeneron Pharma Methods for treating cancer using a combination of adoptive cell therapy and a targeted immunocytokine
WO2024112806A1 (en) * 2022-11-21 2024-05-30 Moonwalk Biosciences, Inc. Generation and use of epigenetic maps for drug discovery
WO2024211478A1 (en) 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a lymphotoxin beta receptor agonist
WO2024243511A1 (en) 2023-05-25 2024-11-28 Regeneron Pharmaceuticals, Inc. T cell receptors that bind presented hpv16-, mart1-, cmv-, ebv-, or influenza- peptides
TW202520975A (zh) * 2023-08-09 2025-06-01 英商劍橋企業有限公司 基因改造之囓齒動物及囓齒動物細胞以及其等用途
WO2025064738A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Dntt 250-258 off-target peptides and uses thereof
WO2025064761A1 (en) 2023-09-22 2025-03-27 Regeneron Pharmaceuticals, Inc. Kras10-18 g12d off-target peptides and uses thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958678A (en) 1986-08-21 1999-09-28 The Trustees Of Columbia University In The City Of New York DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
DE69034263D1 (de) 1989-07-25 2009-04-02 Cell Genesys Inc Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen
US5574205A (en) 1989-07-25 1996-11-12 Cell Genesys Homologous recombination for universal donor cells and chimeric mammalian hosts
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9100481D0 (en) 1991-01-10 1991-02-20 Inst Nat Sante Rech Med Genetically engineered mice
AU2661692A (en) 1991-09-19 1993-04-27 President And Fellows Of Harvard College Transgenic mhc class i and class ii antigen-deficient mammals
EP0663952A4 (en) 1992-09-11 1997-06-11 Univ California Transgenic non-human animals having targeted lymphocyte transduction genes.
US5523226A (en) * 1993-05-14 1996-06-04 Biotechnology Research And Development Corp. Transgenic swine compositions and methods
GB9315303D0 (en) 1993-07-23 1993-09-08 Zeneca Ltd Polypeptide
US5965787A (en) 1995-08-31 1999-10-12 Mayo Foundation For Medical Education And Research HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
US6002066A (en) 1996-01-16 1999-12-14 Ortho Pharmaceutical Corp. H2-M modified transgenic mice
WO1997032603A1 (en) 1996-03-05 1997-09-12 The Scripps Research Institute Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens
ES2301183T3 (es) 1996-12-03 2008-06-16 Amgen Fremont Inc. Anticuerpo completamente humano que se une al receptor del egfr.
PT1017721E (pt) 1997-09-16 2009-05-07 Univ Oregon Health & Science Moléculas de mhc recombinantes úteis para manipulação de células t específicas do antigénio
US6372955B1 (en) 1998-02-17 2002-04-16 Ortho Mcneil Pharmaceutical, Inc. Methods for Producing B cells and antibodies from H2-O modified transgenic mice
AU1023401A (en) 1999-10-12 2001-04-23 Institut Pasteur Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US7462486B2 (en) 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
US20030124524A1 (en) 2000-06-23 2003-07-03 Kenneth Kornman Screening assays for identifying modulators of the inflammatory or immune response
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050050580A1 (en) 2000-12-13 2005-03-03 Masashi Gotoh Transgenic animal expressing hla-a24 and utilization thereof
DK1409646T3 (da) 2000-12-19 2012-08-06 Altor Bioscience Corp Transgene dyr omfattende et humaniseret immunsystem
FR2827302B1 (fr) 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
WO2003020763A2 (en) * 2001-08-31 2003-03-13 Avidex Limited Soluble t cell receptor
EP1994824A1 (en) 2001-11-15 2008-11-26 Kirin Pharma Kabushiki Kaisha Chimeric non-human animal
IL162111A0 (en) 2001-12-22 2005-11-20 4Antibody Ag Method for the generation of generically modified vertebrate precursor lymphocytes and use thereof for the production of heterologo
US8895020B2 (en) 2002-04-19 2014-11-25 Washington University Single chain trimers and uses therefor
DE10244457A1 (de) 2002-09-24 2004-04-01 Johannes-Gutenberg-Universität Mainz Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
US20060156419A1 (en) 2002-10-30 2006-07-13 The Wistar Institute Of Anatomy And Biology Mouse model for autoimmune disorders
US7663017B2 (en) 2003-07-30 2010-02-16 Institut Pasteur Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
JP4857450B2 (ja) 2004-03-09 2012-01-18 財団法人名古屋産業科学研究所 ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物
DK1802193T3 (da) 2004-10-19 2014-06-10 Regeneron Pharma Fremgangsmåde til frembringelse af en homozygot mus til genetisk modifikation
EP2016102B1 (en) 2006-05-03 2012-03-21 Government of the United States of America, Represented by the Secretary, Department of Health and Human Services Chimeric t cell receptors and related materials and methods of use
EP1878798A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies
EP1878342A1 (en) 2006-07-13 2008-01-16 Institut Pasteur Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
CN101534859B (zh) * 2006-09-08 2017-06-09 米迪缪尼有限公司 人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用
US9388425B2 (en) 2006-10-20 2016-07-12 Trustees Of Boston University Tunable genetic switch for regulating gene expression
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
US20090271884A1 (en) 2008-03-07 2009-10-29 Regeneron Pharmaceuticals, Inc. ES Cell-Derived Mice From Diploid Host Embryo Injection
US20090328240A1 (en) 2008-06-24 2009-12-31 Sing George L Genetically modified mice as predictors of immune response
WO2010107400A1 (en) 2009-03-20 2010-09-23 Agency For Science, Technology And Research Genetically modified animal and method of obtaining the same
EP2564695B1 (en) 2009-07-08 2015-04-15 Kymab Limited Animal models and therapeutic molecules
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
GB0917090D0 (en) 2009-09-29 2009-11-11 Ucl Biomedica Plc T-cell receptor
WO2011044186A1 (en) 2009-10-06 2011-04-14 The Board Of Trustees Of The University Of Illinois Human single-chain t cell receptors
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
US9695410B2 (en) 2010-07-15 2017-07-04 Technion Research & Development Foundation Limited Isolated high affinity entities with T-cell receptor like specificity towards native complexes of MHC class II and glutamic acid decarboxylase (GAD) autoantigenic peptides
US9557323B2 (en) 2010-09-24 2017-01-31 The United States Of America As Represented By The Secretary Of The Navy Humanized transgenic mouse model
US10765093B2 (en) 2010-11-27 2020-09-08 James Zhu Humanized transgenic animal
US9043996B2 (en) 2011-10-28 2015-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
EP2771357B1 (en) 2011-10-28 2018-07-18 Regeneron Pharmaceuticals, Inc. Genetically modified t cell receptor mice
EP2770822B9 (en) 2011-10-28 2019-12-11 Regeneron Pharmaceuticals, Inc. Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules
BR112014008529A2 (pt) 2011-10-28 2017-04-18 Regeneron Pharma il-6 humanizado e receptor de il-6
US9591835B2 (en) 2011-10-28 2017-03-14 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex animals
DK2770821T3 (da) 2011-10-28 2017-11-27 Regeneron Pharma Genetisk modificerede major histocompatibility-kompleks-mus
PT3939423T (pt) 2012-11-05 2024-05-29 Regeneron Pharma Animais não humanos geneticamente modificados e métodos de utilização dos mesmos
EP3543253B1 (en) 2013-02-20 2024-03-27 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
HRP20181866T1 (hr) 2013-02-22 2019-01-25 Regeneron Pharmaceuticals, Inc. Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
CA2902543A1 (en) * 2013-03-11 2014-10-09 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
CA2903025C (en) 2013-03-11 2025-10-07 Regeneron Pharmaceuticals, Inc. TRANSGENIC MICE EXPRESSING CHIMERIC MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) CLASS II MOLECULES

Also Published As

Publication number Publication date
KR102699643B1 (ko) 2024-08-28
JP2018513683A (ja) 2018-05-31
PL3280257T3 (pl) 2023-10-23
HUE064168T2 (hu) 2024-02-28
KR20170133498A (ko) 2017-12-05
MX2023002653A (es) 2023-03-28
PT3280257T (pt) 2023-09-12
CN107666828A (zh) 2018-02-06
US11259510B2 (en) 2022-03-01
BR112017021250A2 (pt) 2018-06-26
LT3280257T (lt) 2023-09-25
CA3223798A1 (en) 2016-10-13
JP7555515B1 (ja) 2024-09-24
IL284809B2 (en) 2023-03-01
EP3280257B1 (en) 2023-06-07
IL284809A (en) 2021-08-31
IL318990A (en) 2025-04-01
US20180139940A1 (en) 2018-05-24
HK1250884A1 (en) 2019-01-18
DK3280257T3 (da) 2023-09-04
IL254775A0 (en) 2017-12-31
AU2016246698A1 (en) 2017-10-26
RS64540B1 (sr) 2023-09-29
RU2017137786A3 (es) 2019-09-30
JP2024133736A (ja) 2024-10-02
EP4248744A2 (en) 2023-09-27
ES2954865T3 (es) 2023-11-27
RU2017137786A (ru) 2019-05-08
IL297097B1 (en) 2025-03-01
AU2022221563A1 (en) 2022-10-13
AU2025203245A1 (en) 2025-05-29
IL297097A (en) 2022-12-01
IL284809B (en) 2022-11-01
KR20240132525A (ko) 2024-09-03
JP6796597B2 (ja) 2020-12-09
CN113349159A (zh) 2021-09-07
CA2980771C (en) 2024-02-06
JP2022140609A (ja) 2022-09-26
SG11201707691WA (en) 2017-10-30
JP2020115896A (ja) 2020-08-06
JP7763820B2 (ja) 2025-11-04
NZ736031A (en) 2022-07-29
JP2023174872A (ja) 2023-12-08
WO2016164492A2 (en) 2016-10-13
EP3280257A2 (en) 2018-02-14
CN113349159B (zh) 2022-11-11
AU2022221563B2 (en) 2025-05-29
CN107666828B (zh) 2021-04-09
CA2980771A1 (en) 2016-10-13
US20220174921A1 (en) 2022-06-09
HRP20231039T1 (hr) 2023-12-22
SI3280257T1 (sl) 2023-10-30
WO2016164492A3 (en) 2016-12-15
SMT202300408T1 (it) 2024-01-10
FI3280257T3 (fi) 2023-09-07
AU2016246698B2 (en) 2022-06-02
EP4248744A3 (en) 2023-12-27
RU2732628C2 (ru) 2020-09-21
IL297097B2 (en) 2025-07-01
SG10201909320UA (en) 2019-11-28

Similar Documents

Publication Publication Date Title
MX2017012829A (es) Respuestas inmunitarias mediadas por células t humanizadas en animales no humanos.
CY1121869T1 (el) Ποντικοι με γενετικα τροποποιημενο μειζον συμπλεγμα ιστοσυμβατοτητας
EP4374690A3 (en) Mice expressing humanized t-cell co-receptors
CY1125424T1 (el) Μη-ανθρωπινα ζωα που εκφραζουν ανθρωποποιημενο cd3 συμπλοκο
MX2023010796A (es) Ratones modificados geneticamente que comprenden componentes del sistema inmunitario celular humanizados con diversidad mejorada del repertorio del receptor de celulas t beta (tcrb).
NZ736031A9 (en) Humanized t cell mediated immune responses in non-human animals
CY1120945T1 (el) Γενετικως τροποποιημενοι ποντικοι υποδοχεα τ κυτταρων
MX2017009459A (es) Célula t asesina universal.
UY36471A (es) Anticuerpos contra el inmunorreceptor (tigit) de linfocitos t con dominios ig y motivos de inhibición del inmunorreceptor basados en tirosina (itim)
MX373286B (es) Roedores humanizados que expresan cadenas pesadas que contienen dominios vl.
JP2016506761A5 (es)
MX2016013158A (es) Productos de celulas t modificadas de genes de composicion definida.
MX2019006734A (es) Sistemas y metodos para secuenciar receptores de linfocitos t, y usos de estos.
MX2022001202A (es) Ratones con genes insertados de sirp¿-il15 humanizadas y métodos para usarlos.
BR112015029904A2 (pt) animais geneticamente estéreis
MX2021013336A (es) Anticuerpos y receptores de antigeno quimericos especificos para cd19.
EP4249507A3 (en) Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules
BR112014009941A2 (pt) camundongos transgênicos expressando moléculas do complexo de histocompatibilidade principal (mhc) quimérico classe ii
CY1119071T1 (el) Εξανθρωποποιημενα il-7 τρωκτικα
BR112019021857A2 (pt) Métodos e composições de célula t aperfeiçoada
AR116048A1 (es) Composiciones y métodos para reprogramar receptores de células t (tcr) usando proteínas de fusión
RU2019140867A (ru) Nsg мыши, не имеющие mhc класса i и класса ii
BR112022006782A2 (pt) Receptores de citocina quiméricos
Juchno et al. Reproduction biology of common nase Chondrostoma nasus (Pisces, Cyprinidae)
Delgado-de-Molina-Acevedo et al. Statistics of the European and associated Purse seine and baitboat fleets, in the Atlantic ocean.